Goldman Sachs reduces share in Orphazyme and drops below 5 percent boundary
Orphazyme's life on the stock exchange has been hectic in recent weeks.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
US company Goldman Sachs has divested shares in Danish biotech firm Orphazyme, and as of June 17, owns less than 5 percent of the company, Orphazyme reported on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
